1. Incretin-based therapy: renal effects
   Anton Ivanovich Korbut et al, 2016, DM CrossRef
2. Impact of liraglutide versus atorvastatin on cardiovascular changes in rat model of adenine induced chronic renal failure
   Shata Ahmed et al, 2017, Afr. J. Pharm. Pharmacol. CrossRef
3. Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
   Janaina Paulini et al, 2016, Stem Cells International CrossRef
4. Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats
   Hanaa H. Gaballah et al, 2017, Biomedicine & Pharmacotherapy CrossRef
5. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
   Marcel H A Muskiet et al, 2017, Nat Rev Nephrol CrossRef
6. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner
   Rui Wei et al, 2016, American Journal of Physiology-Endocrinology and Metabolism CrossRef
7. Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin
   Scott C. Thomson et al, 2017, American Journal of Physiology-Renal Physiology CrossRef
8. Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats
   Tsukasa Nozu et al, 2018, Journal of Gastroenterology and Hepatology CrossRef
9. Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
   Leena Liljedahl et al, 2017, Physiol Rep CrossRef
10. Animal Models of Diabetic Kidney Disease
    Isabel Nguyen et al, 2019 CrossRef
11. The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome
    Leena Liljedahl et al, 2019, Physiol Rep CrossRef
12. Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
    Ajay Sood et al, 2019, Metabolic Syndrome and Related Disorders CrossRef
13. Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?
    Celeste Coco et al, 2019, IJMS CrossRef
14. Liraglutide Improves Renal Endothelial Function in Obese Zucker Rats on a High-Salt Diet
    Vijayakumar Sukumaran et al, 2019, J Pharmacol Exp Ther CrossRef
15. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α
    Kim A. Connelly et al, 2016, Journal of Diabetes CrossRef
16. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells
    Yael Einbinder et al, 2016, Diabetes Metab Res Rev CrossRef
17. Rodent models of diabetic kidney disease: human translatability and preclinical validity
    Frederikke E. Sembach et al, 2020, Drug Discovery Today CrossRef
18. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
    Daiji Kawanami et al, 2020, Front. Pharmacol. CrossRef
19. Meta‑analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy
    Wei Liu et al, 2019, Exp Ther Med CrossRef
20. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.
    Shuangli Yang et al, 2020, Am J Physiol Endocrinol Metab CrossRef
21. Renal protection with glucagon-like peptide-1 receptor agonists
    Martina Vitale et al, 2020, Current Opinion in Pharmacology CrossRef
22. Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats
    Heba A. Habib et al, 2020, European Journal of Pharmacology CrossRef
23. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats
    Shohei Yamada et al, 2021, Clin Exp Nephrol CrossRef
24. Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide
    Jennifer Cessario et al, 2021, Pharmacol. Rep CrossRef
25. Improvement of cognitive function, glucose and lipid homeostasis and serum osteocalcin levels by liraglutide in diabetic rats
    Amina Ahmed Sedky, 2021, Fundam Clin Pharmacol CrossRef
26. Reduction in TNF alpha and oxidative stress by liraglutide: Impact on ketamine-induced cognitive dysfunction and hyperlocomotion in rats
    Amina Ahmed Sedky et al, 2021, Life Sciences CrossRef
27. Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression
    Mona K. Tawfik et al, 2021, Mol Biol Rep CrossRef
28. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
    Alba Rojano Toimil et al, 2021, JCM CrossRef
29. Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases
    Natalie Youssef et al, 2021, Biomedicines CrossRef
30. Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease—From Bench to Bedside
    Susanne B. Nicholas, 2021, Advances in Chronic Kidney Disease CrossRef
31. Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
    Domenico Tricò et al, 2021, Advances in Chronic Kidney Disease CrossRef
32. Peptides of Laennec® preparation that contribute to the elimination of endotheliopathy
    I. Yu. Torshin et al, 2022, Farmakoèkonomika CrossRef
33. Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
    Sok Cin Tye et al, 2022, Front. Pharmacol. CrossRef
34. Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy
    Qin Zhang et al, 2021, CMC CrossRef
35. Liraglutide ameliorates gentamicin-induced acute kidney injury in rats via PGC-1α- mediated mitochondrial biogenesis: Involvement of PKA/CREB and Notch/Hes-1 signaling pathways
    Abeer Elkhoely, 2023, International Immunopharmacology CrossRef
36. The impact of liraglutide treatment on erectile function of the diabetic rats
    Serkan GÖNÜLTAŞ et al, 2023, Eur Res J CrossRef
37. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis
    Abolfazl Akbari et al, 2024, Journal of Diabetes Research CrossRef
38. The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
    Zi Guo, 2024, Pharmacol. Rep CrossRef
39. Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin
    Ding-Cheng Chan et al, 2024, Tissue and Cell CrossRef
40. Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
    Aly M. Abdelrahman et al, 2024, JCM CrossRef